Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed predominantly positive progress: pivotal trial enrollment complete, clear timelines (top-line Q3 2026), expanded pipeline (AMX318 nomination), AMX114 Fast Track and favorable safety, and a cash runway into 2028. Near-term cautions include a reduced cash balance versus the prior quarter, a $4M milestone payment, modeled placebo/powering conservatism, and the binary risk around the Phase III readout and subsequent regulatory/ commercialization steps. Overall, the positives — clinical progress, pipeline expansion, cost discipline, and adequate cash runway — outweigh the near-term operational and clinical uncertainties.Company Guidance
Phase III LUCIDITY Initiation and Enrollment Complete
Completed recruitment for the pivotal Phase III LUCIDITY trial of Avexatide (90 mg daily) in post-bariatric hypoglycemia (PBH); expect to randomize and dose remaining eligible participants this month and deliver top-line data in Q3 2026.
Strong Clinical Efficacy Signal from Prior Trials
Five prior Avexatide trials informed LUCIDITY; Phase 2 data showed a 64% least squares mean reduction versus baseline in composite level 2 and 3 hypoglycemic events (p=0.0031). Phase 2b 90 mg showed ~64–66% effect with median patient event rate of zero.
Regulatory and Commercial Preparations Underway
NDA drafting and regulatory preparations underway to enable rapid submission following positive top-line data; commercial buildout includes medical affairs hires, market research, disease education, and market access planning targeting a potential 2027 launch if approved.
Pipeline Expansion and New Development Candidate
Announced nomination of AMX318 (long-acting GLP-1 receptor antagonist) as a development candidate in January; IND-enabling studies underway with IND targeted for 2027 — supports lifecycle and broader GLP-1 antagonist strategy.
AMX114 Progress in ALS
AMX114 received Fast Track designation for ALS; cohort 1 of Phase 1 LUMINA showed favorable safety/tolerability with no treatment-related serious adverse events, enabling progression to cohort 2 and expected completion of cohort 2 enrollment this month. Biomarker data from cohort 1 planned in H1 2026.
Improved Financial Position and Cash Runway Extended
Ended Q4 with $317 million in cash and marketable securities (down from $344 million at end of Q3), with management stating an anticipated cash runway into 2028 to fund key milestones including LUCIDITY top-line readout and potential NDA/commercial activities.
Quarterly Expense Reductions
Total operating expenses for Q4 were $36.6 million, down 8% year-over-year. R&D was $21.2 million (down from $22.9 million in Q4 2024, ≈7.4% decrease) and SG&A was $15.4 million (down from $17.1 million in Q4 2024, ≈10% decrease). Non-cash stock-based compensation was $6.4 million vs $6.8 million prior quarter (≈5.9% decrease).
Market Opportunity Quantified
Internal analysis and literature triangulation estimate ≈160,000 people living with PBH in the U.S., reinforcing a sizable orphan-market opportunity and informing go-to-market planning.
AMLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $15.30 | $14.11 | -7.78% |
Nov 06, 2025 | $13.24 | $12.46 | -5.89% |
Aug 07, 2025 | $8.19 | $7.84 | -4.27% |
May 08, 2025 | $4.87 | $4.58 | -5.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amylyx Pharmaceuticals Inc (AMLX) report earnings?
Amylyx Pharmaceuticals Inc (AMLX) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Amylyx Pharmaceuticals Inc (AMLX) earnings time?
Amylyx Pharmaceuticals Inc (AMLX) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMLX EPS forecast?
AMLX EPS forecast for the fiscal quarter 2026 (Q1) is -0.33.
